Skip to main content
. 2018 Jan 8;9(6):6924–6937. doi: 10.18632/oncotarget.24023

Figure 7.

Figure 7

(A) Inhibition of PDX breast tumors by ZB716 orally administered to mice at 5 and 20 mg/kg, and by fulvestrant 200 mg/kg subcutaneously injected at 200 mg/kg weekly. (B) Downregulation of ERα in tumor tissues treated by fulvestrant, ZB716 5mg/kg, or ZB716 20 mg/kg, respectively.